Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Publikováno v:
Breast Cancer Research
Menopausal hormone therapy (HT) is typically withheld from breast cancer survivors because of concerns about risk for recurrence. Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliabilit
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.
Autor:
Stephanie A. Kennedy, Jennifer Gallagher, Lee G. Wilke, Marlee K. Junker, Nimmi Ramanujam, Torre Michelle Bydlon, Joseph Geradts, J. Quincy Brown, William T. Barry
Publikováno v:
Breast Cancer Research : BCR
Introduction Residual cancer following breast conserving surgery increases the risk of local recurrence and mortality. Margin assessment presents an unmet clinical need. Breast tissue is markedly heterogeneous, which makes distinguishing small foci o
Autor:
M. Villalobos, José Antonio Muñoz-Gámez, R. Guerrero, M. T. Valenzuela, José Mariano Ruiz de Almodóvar, Escarlata López, María Isabel Núñez, Joaquina Martínez-Galán, Rosario Del Moral, Francisco Javier Oliver, David Martín-Oliva
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Breast Cancer Research
instname
Breast Cancer Research
This article is online at: http://breast-cancer-research.com/content/7/5/R690
[Introduction] Radiotherapy outcomes might be further improved by a greater understanding of the individual variations in normal tissue reactions that determine tolera
[Introduction] Radiotherapy outcomes might be further improved by a greater understanding of the individual variations in normal tissue reactions that determine tolera
Autor:
Laurence N. Kolonel, Song-Yi Park, Melissa A. Little, Shannon M. Conroy, Gertraud Maskarinec, Ian Pagano
Publikováno v:
Breast Cancer Research : BCR
Introduction Mammographic density, a strong predictor for breast cancer incidence, may also worsen prognosis in women with breast cancer. This prospective analysis explored the effect of prediagnostic mammographic density among 607 breast cancer case
Autor:
David Van Den Berg, Malcolm C. Pike, Yuri R. Parisky, Wendy J. Mack, Christopher A. Haiman, Sue A. Ingles, Sarah J. Lord, Wei Wang, Giske Ursin, Howard N. Hodis
Publikováno v:
Breast Cancer Research
Introduction Mammographic density is a strong independent risk factor for breast cancer, and can be modified by hormonal exposures. Identifying genetic variants that determine increases in mammographic density in hormone users may be important in und
Publikováno v:
Breast Cancer Research : BCR
There is a reported increased incidence of contralateral disease at presentation of invasive lobular cancer (ILC). In our unit breast MRI is undertaken to assess the extent of all newly diagnosed ILC. If mastectomy is planned MRI is still carried out
Autor:
Helena Hwang, Brian Z. Ring, Marshall T Schreeder, Nancy Watroba, Robert S. Seitz, Christine Murekeyisoni, Swati Kulkarni, Noel C Estopinal, Douglas T. Ross, David G. Hicks, Thaer Khoury, Rodney A. Beck
Publikováno v:
Breast Cancer Research : BCR
Introduction The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. Methods A dataset
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Autor:
Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin
Publikováno v:
Breast Cancer Research : BCR
Introduction Neoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy r
Autor:
Sarah Kirk, Tania Szado, Lukas C. Amler, Young-Hyuck Im, Jennifer Eng-Wong, Giampaolo Bianchini, Pinuccia Valagussa, Tadeusz Pienkowski, Luca Gianni, Giulia Bianchi, Lila Zabaglo, Mitch Dowsett, Astrid Kiermaier, Mei Ching Liu, Ling Ming Tseng
Publikováno v:
Breast Cancer Research : BCR
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assess